Antifungal susceptibility of invasive Candida bloodstream isolates from the Asia-Pacific region

Medical Mycology

Volumn 54, Issue 5, 2016, Pages 471-477

  Tan, Thean Yen ^a   Hsu, Li Yang ^b   Alejandria, Marissa M ^c   Chaiwarith, Romanee ^d   Chinniah, Terrence ^e   Chayakulkeeree, Methee ^f   Choudhury, Saugata ^g   Chen, Yen Hsu ^h,i,j   Shin, Jong Hee ^k   Kiratisin, Pattarachai ^f   Mendoza, Myrna ^l   Prabhu, Kavitha ^e   Supparatpinyo, Khuanchai ^d   Tan, Ai Ling ^m   Phan, Xuan Thi ⁿ   Tran, Thi Thanh Nga ⁿ   Nguyen, Gia Binh ^o   Doan, Mai Phuong ^o   Huynh, Van An ^p   Nguyen, Su Minh Tuyet ^p   Tran, Thanh Binh ^q   Van Pham, Hung ^q   more..

^a CHANGI GENERAL HOSPITAL   (Singapore)

^b NATIONAL UNIVERSITY HEALTH SYSTEM   (Singapore)

^c UNIVERSITY OF THE PHILIPPINES MANILA   (Philippines)

^d Maharaj Nakorn Chiang Mai Hospital   (Thailand)

^e RIPAS HOSPITAL   (Brunei Darussalam)

^f MAHIDOL UNIVERSITY   (Thailand)

^g TAN TOCK SENG HOSPITAL   (Singapore)

^h KAOHSIUNG MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

ⁱ NATIONAL CHIAO TUNG UNIVERSITY   (Taiwan)

^j KAOHSIUNG MEDICAL UNIVERSITY   (Taiwan)

^k Chonnam National University Medical School   (South Korea)

^l National Kidney and Transplant Institute Philippines   (Philippines)

^m SINGAPORE GENERAL HOSPITAL   (Singapore)

ⁿ CHO RAY HOSPITAL   (Viet Nam)

^o BACH MAI HOSPITAL   (Viet Nam)

^p Gia Dinh People's Hospital   (Viet Nam)

^q Nguyen Tri Phuong Hospital   (Viet Nam)

more..

Author keywords

antifungal resistance; candidemia; echinocandin; fluconazole; microbiology; susceptibility testing

Indexed keywords

AMPHOTERICIN; AMPHOTERICIN B; ANIDULAFUNGIN; CASPOFUNGIN; ECHINOCANDIN; FLUCONAZOLE; MICAFUNGIN; VORICONAZOLE; ANTIFUNGAL AGENT;

ANTIFUNGAL SUSCEPTIBILITY; ARTICLE; BLOODSTREAM INFECTION; BROTH DILUTION; BRUNEI DARUSSALAM; CANDIDA; CANDIDA ALBICANS; CANDIDA DUBLINIENSIS; CANDIDA GLABRATA; CANDIDA PARAPSILOSIS; CANDIDA RUGOSA; CANDIDA TROPICALIS; FUNGUS ISOLATION; HIGH RISK PATIENT; HUMAN; IN VITRO STUDY; MAJOR CLINICAL STUDY; MULTICENTER STUDY; OBSERVATIONAL STUDY; PHILIPPINES; PICHIA KUDRIAVZEVII; PREVALENCE; PROSPECTIVE STUDY; SINGAPORE; SOUTH KOREA; TAIWAN; THAILAND; VIET NAM; WICKERHAMOMYCES ANOMALUS; CANDIDEMIA; CLASSIFICATION; CLINICAL TRIAL; DRUG EFFECTS; ISOLATION AND PURIFICATION; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; SOUTHEAST ASIA;

ANTIFUNGAL AGENTS; ASIA, SOUTHEASTERN; CANDIDA; CANDIDEMIA; HUMANS; MICROBIAL SENSITIVITY TESTS; PREVALENCE; PROSPECTIVE STUDIES;

EID: 84981719818     PISSN: 13693786     EISSN: 14602709     Source Type: Journal    
DOI: 10.1093/mmy/myv114     Document Type: Article

References (30)

1. Hajjeh RA, Sofair AN, Harrison LH et al. Incidence of bloodstream infections due to Candida species and in vitro susceptibilities of isolates collected from 1998 to 2000 in a populationbased active surveillance program. J Clin Microbiol 2004; 42: 1519-1527
2. Colombo AL, Nucci M, Salomao R et al. High rate of nonalbicans candidemia in Brazilian tertiary care hospitals. Diagn Microbiol Infect Dis 1999; 34: 281-286
3. Foongladda S, Sakulmaiwatana P, Petlum P et al. Candida species, genotypes and antifungal susceptibility of Candida isolates from blood samples of patients at the largest tertiary care hospital in Thailand during 1999-2002. JMed Assoc Thai 2004; 87: 92-99
4. Tan TY, Tan AL, Tee NW et al. The increased role of nonalbicans species in candidaemia: results from a 3-year surveillance study. Mycoses 2010; 53: 515-521
5. Jung SI, Shin JH, Song JH et al. Multicenter surveillance of species distribution and antifungal susceptibilities of Candida bloodstream isolates in South Korea. MedMycol 2010; 48: 669-674
6. Kothavade RJ, Kura MM, Valand AG et al. Candida tropicalis: its prevalence, pathogenicity and increasing resistance to fluconazole. J Med Microbiol 2010; 59(Pt 8): 873-880
7. Pfaller MA, Jones RN, CastanheiraM. Regional data analysis of Candida non-albicans strains collected in United States medical sites over a 6-year period, 2006-2011. Mycoses 2014; 57: 602-611
8. Koehler AP, Chu KC, Houang ET et al. Simple, reliable, and costeffective yeast identification scheme for the clinical laboratory. J Clin Microbiol 1999; 37: 422-426
9. Leaw SN, Chang HC, Sun HF et al. Identification of medically important yeast species by sequence analysis of the internal transcribed spacer regions. J Clin Microbiol 2006; 44: 693-699
10. CLSI. Interpretive Criteria for Identification of Bacteria and Fungi by DNA Target Sequencing; Approved Guideline. CLSI document MM18-A. Wayne, PA: Clinical and Laboratory Standards Institute; 2008
11. CLSI. Reference Method for Broth Dilution Antifungal Susceptibility Testing of Yeasts; Fourth Informational Supplement. CLSI document M27-S4. Wayne, PA: Clinical and Laboratory Standards Institute; 2012
12. Castanheira M, Woosley LN, Diekema DJ et al. Low prevalence of fks1 hot spot 1 mutations in a worldwide collection of Candida strains. Antimicrob Agents Chemother 2010; 54: 2655-2659
13. Pfaller MA, Espinel-Ingroff A, Canton E et al. Wild-type MIC distributions and epidemiological cutoff values for amphotericin B, flucytosine, and itraconazole and Candida spp. as determined by CLSI broth microdilution. J Clin Microbiol 2012; 50: 2040-2046
14. Arendrup MC. Epidemiology of invasive candidiasis. Curr Opin Crit Care 2010; 16: 445-452
15. Nucci M, Queiroz-Telles F, Alvarado-Matute T et al. Epidemiology of candidemia in Latin America: a laboratory-based survey. PLoS One 2013; 8: e59373
16. Hsueh PR, Graybill JR, Playford EG et al. Consensus statement on the management of invasive candidiasis in Intensive Care Units in the Asia-Pacific Region. Int J Antimicrob Agents 2009; 34: 205-209
17. Pfaller MA, Diekema DJ, Gibbs DL et al. Results from the ARTEMIS DISK Global Antifungal Surveillance Study, 1997 to 2007: a 10.5-year analysis of susceptibilities of Candida Species to fluconazole and voriconazole as determined by CLSI standardized disk diffusion. J Clin Microbiol 2010; 48: 1366-1377
18. Pfaller MA, Diekema DJ, Rinaldi MG et al. Results from the ARTEMIS DISK Global Antifungal Surveillance Study: a 6.5- year analysis of susceptibilities of Candida and other yeast species to fluconazole and voriconazole by standardized disk diffusion testing. J Clin Microbiol 2005; 43: 5848-5859
19. Fothergill AW, Sutton DA, McCarthy DI et al. Impact of new antifungal breakpoints on antifungal resistance in Candida species. J Clin Microbiol 2014; 52: 994-997
20. Huang YT, Liu CY, Liao CH et al. Antifungal susceptibilities of Candida isolates causing bloodstream infections at a medical center in Taiwan, 2009-2010. Antimicrob Agents Chemother 2014; 58: 3814-3819
21. Xiao M, Fan X, Chen SC et al. Antifungal susceptibilities of Candida glabrata species complex, Candida krusei, Candida parapsilosis species complex and Candida tropicalis causing invasive candidiasis in China: 3 year national surveillance. J Antimicrob Chemother 2015; 70: 802-810
22. Pfaller MA, Messer SA, Hollis RJ et al. Variation in susceptibility of bloodstream isolates of Candida glabrata to fluconazole according to patient age and geographic location in the United States in 2001 to 2007. J Clin Microbiol 2009; 47: 3185-3190
23. Pfaller MA, Moet GJ, Messer SA et al. Geographic variations in species distribution and echinocandin and azole antifungal resistance rates among Candida bloodstream infection isolates: report from the SENTRY Antimicrobial Surveillance Program (2008 to 2009). J Clin Microbiol 2011; 49: 396-399
24. Pfaller MA, Castanheira M, Lockhart SR et al. Frequency of decreased susceptibility and resistance to echinocandins among fluconazole-resistant bloodstream isolates of Candida glabrata. J Clin Microbiol 2012; 50: 1199-1203
25. Espinel-Ingroff A, Arendrup MC, Pfaller MA et al. Interlaboratory variability of Caspofungin MICs for Candida spp. Using CLSI and EUCAST methods: should the clinical laboratory be testing this agent? Antimicrob Agents Chemother 2013; 57: 5836-5842
26. Pfaller MA, Messer SA, Diekema DJ et al. Use of micafungin as a surrogate marker to predict susceptibility and resistance to caspofungin among 3,764 clinical isolates of Candida by use of CLSI methods and interpretive criteria. J Clin Microbiol 2014; 52: 108-114
27. Shields RK, Nguyen MH, Press EG et al. Anidulafungin and micafungin MIC breakpoints are superior to that of caspofungin for identifying FKS mutant Candida glabrata strains and Echinocandin resistance. Antimicrob Agents Chemother 2013; 57: 6361-6365
28. Oxman DA, Chow JK, Frendl G et al. Candidaemia associated with decreased in vitro fluconazole susceptibility: is Candida speciation predictive of the susceptibility pattern? J Antimicrob Chemother 2010; 65: 1460-1465
29. Shah DN, Yau R, Weston J et al. Evaluation of antifungal therapy in patients with candidaemia based on susceptibility testing results: implications for antimicrobial stewardship programmes. J Antimicrob Chemother 2011; 66: 2146-2151
30. Clancy CJ, Yu VL, Morris AJ et al. Fluconazole MIC and the fluconazole dose/MIC ratio correlate with therapeutic response among patients with candidemia. Antimicrob Agents Chemother 2005; 49: 3171-3177.